核素标记成纤维细胞活化蛋白抑制剂在甲状腺疾病诊疗中的研究进展
Research Progress of Radionuclide-Labeled Fibroblast Activation Protein Inhibitors in the Diagnosis and Treatment of Thyroid Diseases
DOI: 10.12677/acm.2026.1682814, PDF,   
作者: 王锦辉：西安医学院研究生院，陕西 西安；马温惠*：空军军医大学第一附属医院核医学科，陕西 西安
关键词: 甲状腺疾病；甲状腺癌；成纤维细胞活化蛋白抑制剂；PET/CT；Thyroid Diseases； Thyroid Cancer； Fibroblast Activation Protein Inhibitor； PET/CT
摘要: 在甲状腺疾病中，甲状腺癌是最常见的内分泌系统恶性肿瘤，近年来在全球范围内发病率呈快速增长趋势。对于其中部分放射性碘难治与甲状腺髓样癌患者，传统影像检查与治疗手段不能满足精准的诊疗需求。以FAP为靶点的FAP抑制剂(FAPI)具有良好的生物学特性，有望在甲状腺相关疾病中发挥重要作用。本文主要阐述了新型核素标记成纤维细胞活化蛋白抑制剂(FAPI)的作用机制及在甲状腺良恶性疾病相关诊疗的研究进展，以期为新型分子探针在甲状腺疾病诊疗领域的发展与应用提供参考。
Abstract: Among thyroid diseases, thyroid cancer is the most common malignancy of the endocrine system, and its incidence has been increasing rapidly worldwide in recent years. For patients with radioiodine‑refractory thyroid cancer and those with medullary thyroid carcinoma, conventional imaging modalities and therapeutic strategies are often insufficient to meet the demands of precision diagnosis and treatment. Fibroblast activation protein inhibitors (FAPI) that target FAP exhibit favorable biological properties and hold promise for playing a significant role in thyroid‑related diseases. This review focuses on the mechanism of action of novel radionuclide‑labeled FAPI and summarizes the research progress regarding their application in the diagnosis and management of both benign and malignant thyroid disorders, with the aim of providing a reference for the future development and clinical translation of novel molecular probes in the field of thyroid disease.
文章引用：王锦辉, 马温惠. 核素标记成纤维细胞活化蛋白抑制剂在甲状腺疾病诊疗中的研究进展[J]. 临床医学进展, 2026, 16(8): 451-456. https://doi.org/10.12677/acm.2026.1682814

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
[2] 殷德涛, 赵乾. 全球及中国甲状腺癌的发病特征及趋势[J]. 中国普外基础与临床杂志, 2025, 32(6): 687-693.
[3] Ringel, M.D., Sosa, J.A., Baloch, Z., Bischoff, L., Bloom, G., Brent, G.A., et al. (2025) 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer. Thyroid®, 35, 841-985.
https://doi.org/10.1177/10507256251363120
[4] Roshanravan, V., Sadeghi, R., Zakavi, S.R., Norouzbeigi, N. and Aghaee, A. (2023) Unilateral Chronic Parotitis with 68Ga-DOTA-FAPI-04 PET/CT and 18F-FDG PET/CT Imaging in a Case of a Patient with Papillary Thyroid Carcinoma. Clinical Nuclear Medicine, 48, e577-e579.
https://doi.org/10.1097/rlu.0000000000004884
[5] Fu, H., Fu, J., Huang, J., Pang, Y. and Chen, H. (2021) 68Ga-FAPI PET/CT versus 18F-FDG PET/CT for Detecting Metastatic Lesions in a Case of Radioiodine-Refractory Differentiated Thyroid Cancer. Clinical Nuclear Medicine, 46, 940-942.
https://doi.org/10.1097/rlu.0000000000003730
[6] Giovanella, L., Avram, A. and Clerc, J. (2021) Molecular Imaging for Thyrotoxicosis and Thyroid Nodules. Journal of Nuclear Medicine, 62, 20S-25S.
https://doi.org/10.2967/jnumed.120.246017
[7] Zhou, Y., Hou, Y., Yin, C., Gai, Y., Lan, X., Qin, C., et al. (2026) FAPI PET in the Diagnosis and Management of Inflammatory Diseases: Clinical Value and Future Perspectives. Clinical Nuclear Medicine, 51, 35-43.
https://doi.org/10.1097/rlu.0000000000006175
[8] Mu, X., Huang, X., Jiang, Z., Li, M., Jia, L., Lv, Z., et al. (2023) [18F]FAPI-42 PET/CT in Differentiated Thyroid Cancer: Diagnostic Performance, Uptake Values, and Comparison with 2-[18F]FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 50, 1205-1215.
https://doi.org/10.1007/s00259-022-06067-2
[9] Zheng, K., Zhou, W., Yang, J., Zhang, Y., Jiang, C., Xie, A., et al. (2025) [18F]AlF-NOTA-FAPI-04 PET/CT Improves Detection of Subcentimeter Recurrent Lesions in Differentiated Thyroid Cancer. European Journal of Nuclear Medicine and Molecular Imaging, 53, 398-407.
https://doi.org/10.1007/s00259-025-07433-6
[10] Ballal, S., Yadav, M.P., Roesch, F., Satapathy, S., Moon, E.S., Martin, M., et al. (2023) Head-to-Head Comparison of [68Ga]Ga-DOTA.SA.FAPi with [18F]F-FDG PET/CT in Radioiodine-Resistant Follicular-Cell Derived Thyroid Cancers. European Journal of Nuclear Medicine and Molecular Imaging, 51, 233-244.
https://doi.org/10.1007/s00259-023-06404-z
[11] Schmidkonz, C., Kuwert, T., Atzinger, A., Cordes, M., Schett, G., Ramming, A., et al. (2022) Fibroblast Activation Protein Inhibitor Imaging in Nonmalignant Diseases: A New Perspective for Molecular Imaging. Journal of Nuclear Medicine, 63, 1786-1792.
https://doi.org/10.2967/jnumed.122.264205
[12] Karamian, F., Sadeghi, R., Aghaee, A., Askari, E. and Roustaei, H. (2024) Nonmalignant 68Ga-FAPI-46 Uptake in 2 Cases of TENIS Syndrome: Comparison with 18F-FDG. Clinical Nuclear Medicine, 49, e213-e214.
https://doi.org/10.1097/rlu.0000000000005160
[13] Chen, Y., Zang, J., Wu, Z. and Miao, W. (2024) 68Ga-FAPI-RGD PET/CT Detected Skull Metastasis Better than 18F-FDG in a Patient with Radioiodine-Refractory Differentiated Thyroid Cancer. Clinical Nuclear Medicine, 49, 964-965.
https://doi.org/10.1097/rlu.0000000000005301
[14] Xu, T., Zhang, Y., Wu, R., Ding, H. and Chen, Y. (2022) 68Ga-DOTA-FAPI-04 PET/CT Imaging in a Case of Radioactive Iodine-Induced Chronic Parotitis. Clinical Nuclear Medicine, 47, 1082-1083.
https://doi.org/10.1097/rlu.0000000000004416
[15] Ghahraman, M., Sahafi, P., Samadi, M.H., Aryana, K. and Aghaee, A. (2025) Remarkable 99mTc-FAPI-46 Uptake in a Patient with Anaplastic Thyroid Carcinoma: A Promising Step in Theranostic Field. Clinical Nuclear Medicine, 50, e365-e367.
https://doi.org/10.1097/rlu.0000000000005746
[16] Can, C., Gündoğan, C., Güzel, Y., Kaplan, İ. and Kömek, H. (2021) 68Ga-FAPI Uptake of Thyroiditis in a Patient with Breast Cancer. Clinical Nuclear Medicine, 46, 683-685.
https://doi.org/10.1097/rlu.0000000000003637
[17] Agrawal, N., Mahdi, R.A., Singh, H., Mittal, B.R., Kumar, R. and Taneja, S. (2026) Pembrolizumab-Induced Retroperitoneal Fibrosis Detected on 68Ga-FAPi PET/CT. Clinical Nuclear Medicine, 51, e305-e306.
https://doi.org/10.1097/rlu.0000000000006130
[18] Su, D., Li, Z., Deng, J., Qiu, C. and Chen, Y. (2023) Increased 68Ga-FAPI Activity in Benign Pulmonary Nodules. Clinical Nuclear Medicine, 48, 439-441.
https://doi.org/10.1097/rlu.0000000000004592
[19] Chen, Y., Zheng, S., Zang, J., Shao, Z., Tu, D., Liu, Q., et al. (2025) [68Ga]Ga-LNC1007 versus 2-[18F]FDG in the Evaluation of Patients with Metastatic Differentiated Thyroid Cancer: A Head-to-Head Comparative Study. European Journal of Nuclear Medicine and Molecular Imaging, 52, 683-692.
https://doi.org/10.1007/s00259-024-06930-4
[20] Fu, H., Wu, J., Huang, J., Sun, L., Wu, H., Guo, W., et al. (2022) 68Ga Fibroblast Activation Protein Inhibitor PET/CT in the Detection of Metastatic Thyroid Cancer: Comparison with 18F-FDG PET/CT. Radiology, 304, 397-405.
https://doi.org/10.1148/radiol.212430
[21] Shi, X., Lan, W. and Bin, J. (2024) FAPI PET Missed Widespread Bone Marrow Metastases from Follicular Thyroid Cancer That Were Detected by FDG PET. Clinical Nuclear Medicine, 49, e125-e126.
https://doi.org/10.1097/rlu.0000000000005031
[22] Wu, Y., Wang, X., Sun, X., Gao, X., Zhang, S., Shen, J., et al. (2025) Fibroblast Activation Protein Targeting Radiopharmaceuticals: From Drug Design to Clinical Translation. Acta Pharmaceutica Sinica B, 15, 4511-4542.
https://doi.org/10.1016/j.apsb.2025.07.009
[23] Zhou, H., Hong, M., Chai, Y. and Hei, T.K. (2009) Consequences of Cytoplasmic Irradiation: Studies from Microbeam. Journal of Radiation Research, 50, A59-A65.
https://doi.org/10.1269/jrr.08120s
[24] Privé, B.M., Boussihmad, M.A., Timmermans, B., van Gemert, W.A., Peters, S.M.B., Derks, Y.H.W., et al. (2023) Fibroblast Activation Protein-Targeted Radionuclide Therapy: Background, Opportunities, and Challenges of First (Pre)clinical Studies. European Journal of Nuclear Medicine and Molecular Imaging, 50, 1906-1918.
https://doi.org/10.1007/s00259-023-06144-0
[25] Jafari Zarrin Ghabaei, F., Saber Tanha, A., Raeisi, N., Aryana, K. and Barashki, S. (2026) FAP-Targeted Radio-Ligand Therapy in Pancreatic Neuroendocrine Tumor: A Potential Alternative to PRRT. Clinical Nuclear Medicine, 51, e340-e341.
https://doi.org/10.1097/rlu.0000000000006204
[26] Ballal, S., Yadav, M.P., Moon, E.S., Rösch, F., ArunRaj, S.T., Agarwal, S., et al. (2022) First-in-Human Experience with 177Lu-DOTAGA.(SA.FAPi)2 Therapy in an Uncommon Case of Aggressive Medullary Thyroid Carcinoma Clinically Mimicking as Anaplastic Thyroid Cancer. Clinical Nuclear Medicine, 47, e444-e445.
https://doi.org/10.1097/rlu.0000000000004164
[27] Fu, H., Huang, J., Zhao, T., Wang, H., Chen, Y., Xu, W., et al. (2023) Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine-Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study. Clinical Cancer Research, 29, 4740-4750.
https://doi.org/10.1158/1078-0432.ccr-23-1983
[28] Fu, H., Huang, J., Sun, L., Wu, H. and Chen, H. (2022) FAP-Targeted Radionuclide Therapy of Advanced Radioiodine-Refractory Differentiated Thyroid Cancer with Multiple Cycles of 177Lu-FAPI-46. Clinical Nuclear Medicine, 47, 906-907.
https://doi.org/10.1097/rlu.0000000000004260
[29] Raeisi, N., Saber Tanha, A., Gozashti, M.H., Kiamanesh, Z. and Aryana, K. (2025) 177Lu-FAPI-2286 Therapy in a Patient with Radio-Iodine Refractory Papillary Thyroid Carcinoma: A Favorable Clinical and Biochemical Response. Clinical Nuclear Medicine, 50, e315-e316.
https://doi.org/10.1097/rlu.0000000000005728
[30] Ballal, S., Yadav, M.P., Satapathy, S., Roesch, F., Chandekar, K.R., Martin, M., et al. (2025) Long-Term Outcomes in Radioiodine-Resistant Follicular Cell-Derived Thyroid Cancers Treated with [177Lu]Lu-DOTAGA.FAPi Dimer Therapy. Thyroid®, 35, 188-198.
https://doi.org/10.1089/thy.2024.0229

为你推荐